ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On December 12, 2018, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) increased the size of the Board to eight members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Peter Greenleaf to the Board as a Class I Director. Mr. Greenleaf’s term will expire at the Company’s 2020 Annual Meeting of Stockholders.
Mr. Greenleaf will be compensated to the Company’s non-employee director compensation plan as disclosed in the Company’s Proxy Statement on Schedule 14A for the 2018 Annual Meeting of Stockholders (the “Proxy Statement”) including, without limitation, an initial grant of options to purchase 20,000 shares of the Company’s common stock at an exercise price per share that is equal to the closing price per share of the Company’s common stock on the date of the grant.Mr. Greenleaf also will enter into an indemnification agreement with the Company substantially in the form used for other directors as disclosed in the Proxy Statement.
There is no arrangement or understanding between Mr. Greenleaf and any other persons to which Mr. Greenleaf was appointed to serve as a director of the Company.There are no relationships between Mr. Greenleaf and the Company that would require disclosure to Item 404(a) of Regulation S-K.
A copy of the Company’s press release announcing the appointment of Mr. Greenleaf to the Board is attached hereto as Exhibit 99.1.
|
Item 5.02 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated December 13, 2018 |
ANTARES PHARMA, INC. Exhibit
EX-99.1 2 atrs-ex991_7.htm EX-99.1 PRESS RELEASE atrs-ex991_7.htm EXHIBIT 99.1 ANTARES PHARMA ANNOUNCES THE APPOINTMENT OF PETER S. GREENLEAF TO COMPANY’S BOARD OF DIRECTORS EWING,…
To view the full exhibit click here
About ANTARES PHARMA, INC. (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
